sample pages - oncology drug funding 2013
Post on 14-Sep-2014
629 views
DESCRIPTION
How this Report can Help - CXOs / Directors / VPs - First innovative report to provide insights on several new strategic/financial investors willing to fund your company’s growth. - Identify key venture partners contribution and strategic positions on Company ’s Board. - Detailed series co-investors details to identify best investors consortium for your needs. - Access to Numerous deals, structure & size to analyze true value of business model. Venture Partners - Identify new emerging players in drug funding, with their core team and funding preferences. - De-risk the venture by getting real insights through a comprehensive picture. - Infographics design with focused and interactive content, takes no time in filling knowledge gaps. - Virtually cover all oncology focused funding deals occurs in past 10 years with their valuation sizes. Analysts/ Consultants - Explore Top Investors and eliminate your hours of digital search and data curating. - Spend quality time in analyzing finer funding details & decisions making. - Identify paradigm shift in oncology drug funding; with 10 years of funding history covering 500+ companies and 3000+ Deals. - Closely monitor wining deals and M&A activities by bringing more data under analysis. Start-ups / Entrepreneurs - Clearly identify - who will invest in your business and to which extent. - Quickly navigate the complete profiles of focused Investors and their investment strategies. - Identify the extent of funding in each round/series to meet your immediate and future needs. - To design and negotiate on better financial plans to unlock the real value of innovation/assets. - Directly get in touch with oncology focused Venture Partner through Linkedin & E-mail ID. Number of Pages = 570 pages interactive pdf Price = 1495 USD (if directly purchased through OmicsX online store or through wire transfer) 1995 USD (if purchase through Research and Market - An online research report store)TRANSCRIPT
ONCOLOGY
PARTNER
EQUITY
FINANCE
DRUG
A COMPREHENSIVE INTELLIGENCE REPORT ON
Oncology Company Funding Details
Active Venture Capital Firm Pro�les
Venture Partners Professional Pro�les
FUNDING 2013
Funding Round/Series Details
321
502
947
3000
Onc
olog
yFo
cuse
d
+
ONCOLOGY DRUG FUNDING 2013
A Comprehensive Intelligence Report on
Sample Pages
O N C O L O G Y D R U G F U N D I N G 2 0 1 3
19OmicsX - Intelligent BioSolutions
3i Group plc
5AM Ventures
Aberdare Ventures
Abingworth LLP
ABS Ventures
Adams Street Partners, LLC
Advanced Technology Ventures
Advantage Capital Partners
Advent Venture Partners
Aescap Venture
Aglaia Biomedical Ventures B.V
Aisling Capital
Alafi Capital Company LLC
Alliance Technology Ventures
Alloy Ventures
Alta Partners
Amgen Ventures
Anthem Capital Management
Aperture Venture Partners, LLC
Apjohn Ventures Fund
Apple Tree Partners
Apposite Capital LLP
Aravis SA
Arboretum Ventures
ARCH Venture Partners
Arcus Ventures
Ascension Health Ventures
Astellas Venture Management
Athenian Venture Partners
Atlas Venture
Auriga Partners
Aurora Funds
Aurum Ventures MKI
Avalon Ventures
Avlar BioVentures Ltd
AXA Private Equity
Bain Capital Ventures
Baird Capital
Ballast Point Ventures
Bay City Capital LLC
Bayern Kapital GmbH
5000+ Worldwide - Diversified 101 1
101 - 500 USA, Europe - Life Science 31 4
101 - 500 USA 1 - 15 Healthcare 29 1
1001 - 5000 Worldwide 20 - 80 Health Care 100+ 1
1 - 100 USA 5 - 15 Diversified 60+ 1
5000+ USA 5 - 20 Diversified 157 3
1001 - 5000 USA - Diversified 75 4
1001 - 5000 USA 0.5 - 10 Diversified 146 2
201 - 1000 USA, Europe 8 - 25 Diversified 51 7*
101 - 500 Europe 0.5 - 7 Biomedical 12 4
1 - 100 Europe - Life Science 6 5
1000 - 5000 USA 20 - 50 Healthcare 62 3
1 - 100 USA, Europe - Healthcare 11 1
101 - 500 USA 0.5 - 5 Diversified 30 1
501 - 1000 USA 1 - 5 Diversified 31 1
1001 - 5000 USA, Europe - Diversified 65 8
1 - 100 USA, Europe 1 - 10 Biotechnology 12 4
1 - 100 USA 1 - 5 Diversified 7 1
501 - 1000 USA, Europe 1 - 4 Healthcare 6 1
1 - 100 USA 0.5 - 2 Life Science 9 2
101 - 500 USA - Life Science 4 2
101 - 500 USA, Europe 5 - 15 Healthcare 9 4
101 - 500 Worldwide 1 - 10 Diversified 15 3
101 - 500 USA 3 - 7 Healthcare 20 1
1001 - 5000 USA - Diversified 30 11
101 - 500 USA - Life Science 8 3
501 - 1000 USA 10 - 15 Healthcare 21 1
1 - 100 Worldwide - Biotechnology 16 5
1 - 100 USA 1 - 5 Diversified 23 1
1001 - 5000 USA, Europe 0.5 - 5 Diversified 66 2
101 - 500 Worldwide 1 - 5 Diversified 37 2
101 - 500 USA 0.05 - 2.5 Diversified 23 2
1 - 100 Asia Up to 10 Diversified 11 1
101 - 500 USA - Diversified 55 5
101 - 500 Europe - Life Science 10 2
5000+ Worldwide - Diversified 85 3
1001 - 5000 USA 0.1 - 50 Diversified 65 1
1001 - 5000 Worldwide 1 - 10 Diversified 55 3
101- 500 USA 2 - 5 Diversified 12 1
1001 - 5000 Worldwide - Life Science 25 4
101 - 500 Europe - Diversified 20+ 3
Investment Focus
Early Mid LateFunds Name Angel
* Oncology Exit Company
Table A.1: Investment Summary of 321 Investor Firms.
Fund under Management
Investment Preference
Investment Range
Fund Focused Total Comp Oncology Comp
Active Portfolio
in Mn USD in Mn USD
18
Active Companies
Exit Companies
Russia
-3
1
UAE
-1
-
China
32
3
Japan
43
3Korea
-1
-
Taiwan
1-
3
Malaysia
--
1
Singapore
12
3
Finland
-2
2
Germany
517
21
Sweden
-1
4
Norway
35
7
Denmark
23
4
Switzerland
212
10Belgium
22
3
France
54
11
Spain
-1
1
Ireland
11
1
UK
1017
15
Netherland
213
9
Total no. of VCs
Israel
510
7
Austria
-5
-Italy
-1
-
8884
32
Active Companies
Exit Companies
InvestorCompanies
21
22
14
Active Companies
Exit Companies
InvestorCompanies
Oncology Portfolio Companies Infographics – Europe & Asia
EuropE AsiA
InmanyEuropeancountriesincludingGermanyandFrancetheratiobetweenactivecompaniesandtotalnumberofInvestorspresentintheregionisgoingdown,whichmaysignifiesthatoncologyfundingwasonceveryactiveintheregion,butatpresentloosingitscharmamonginvestors.AlsoourpreviousstudiesshowsthattheEuropeanregiondoesnotseeanydampeningeffectinthenumberofoncologybasedstart-ups,whichimpliesthatnowinnovatorsarerelyingmoreonothersourcesofmoneyesp.fromGovernmentFundingetc.
Country wise Distribution of Investors and their 152 Portfolio Companies in Europe and Asia. Figure B.5:
Outof32PortfolioCompaniesExit;18arethroughIPOand12arethroughM&Aactivities.
Total Investor Firms Vs. their Active Portfolio Companies & Exit Companies in Europe.
Figure B.6:
In Asia maximum Exits are through Initial PublicOfferings(IPO).Israelisthemajornumbercontributingcountryandisalsocreditedtohavelargestnumberoftechnologybasedoncologystart-upsinAsia,muchaheadofJapanandChina.
Total Investor Firms Vs. their Active Portfolio Companies & Exit Companies in Asia.
Figure B.7:
O N C O L O G Y D R U G F U N D I N G 2 0 1 3
28 OmicsX - Intelligent BioSolutions
Active Companies
Exit Companies
Russia
-3
1
UAE
-1
-
China
32
3
Japan
43
3Korea
-1
-
Taiwan
1-
3
Malaysia
--
1
Singapore
12
3
Finland
-2
2
Germany
517
21
Sweden
-1
4
Norway
35
7
Denmark
23
4
Switzerland
212
10Belgium
22
3
France
54
11
Spain
-1
1
Ireland
11
1
UK
1017
15
Netherland
213
9
Total no. of VCs
Israel
510
7
Austria
-5
-Italy
-1
-
8884
32
Active Companies
Exit Companies
InvestorCompanies
21
22
14
Active Companies
Exit Companies
InvestorCompanies
Arizona
-1
Active Companies
Exit Companies
2
California
4554
62
Texas
15
5
Louisiana
-2
1
Albama
22
1 Florida
13
4
Washington
514
8Colorado
21
1Minnesota
-1 - Indiana
15
3 Michigan
-4
5Pannsylvania
610
7
New York
15
21
Massachusetts
1836
29
Connecticut
11
7
New Jersey
35
8
Delaware
1-
1
Maryland
47
4
Virginia
-3
4
North Calorina
49
10
Total no. of VCs
Utah
-1
2
Missouri
-1
5
Georgia
1-
1
Illinois
--
7Ohio
-3
3
Oregon
-1 -
Wisconsin
14
2
203
178
97
Active Companies
Exit Companies
InvestorCompanies
62
54
45
Active Companies
Exit Companies
InvestorCompanies
Oncology Portfolio Companies Infographics – USA
unitEd stAtEs AmEricA cAliforniA
ManyoftheUSAstateslikeMassachusetts,Washington,Indiana,Marylandetc.havefairlyhighratioofInvestorstoactiveportfoliocancercompaniesintheregions,thusareshowingpositivefundingenvironmenttowardsoncologyfunding,andisshowingnodampeningeffectinanyofthestate;alsowithhealthyExitportfolioinvestorsarebettingmoreongoodideas.
State wise Distribution of Investors and their 282 Portfolio Companies in USA.Figure B.8:
Total Investor Firms Vs. their Active Portfolio Companies & Exit Companies in USA.
Figure B.9: Total Investor Firms Vs. their Active Portfolio Companies & Exit Companies in California.
Figure B.10:
O N C O L O G Y D R U G F U N D I N G 2 0 1 3
29OmicsX - Intelligent BioSolutions
O N C O L O G Y D R U G F U N D I N G 2 0 1 3
30 OmicsX - Intelligent BioSolutions
Company Therapeutic Area Focus Area Oncology Pipeline Key Technology Platform Collaboration Series A Series B Series C Series D Series E Series F NA
4-Antibody AGOncology,Infectious,Autoimmune,InflammatoryDiseases
Treatment Undisclosed(discovery) Retrocyte Display®
Boehringer IngelheimEvotec AGHuman Genome Sciences Recepta Biopharma
AdventVenture,BioMedPartners,GraziaEquity,LifeSciencesPartners[18.5 Mn USD/2007]
Aarden Pharmaceuticals
Oncology,Infectious,Autoimmune,MetabolicDiseases
Treatment Elevate Ventures[0.5 Mn/2009]
Acacia Pharma Oncology SupportiveCare
APD421(clinical)APD403(clinical)APD515(clinical)APD209(clinical)
GildeHealthcare,LundbeckfondVentures[10 Mn USD/2011]
Acceleron PharmaOncology,Hematologic,MucoskeletalDisorders
Treatment Dalantercept/ACE-041(clinical)CelgeneCorp,Shireplc,Alkermes
AdvancedTechnology,AvalonVentures,FlagshipVentures,PolarisVenture,SutterHillVenturesVenrock[25 Mn USD/2004]
AdvancedTechnology,AvalonVentures,FlagshipVentures,PolarisVenture,SutterHillVentures,Venrock,OrbiMedAdvisors[30 Mn USD/2006]
AdvancedTechnology,AvalonVentures,FlagshipVentures,PolarisVenture,SutterHillVentures,Venrock,OrbiMedAdvi-sors,BessemerVenture[31 Mn USD/2007]
AdvancedTechnology,AvalonVentures,FlagshipVentures,PolarisVenture,SutterHillVentures,Venrock,OrbiMed,Bessemer Venture[30 Mn USD/2011]
Acerta Pharma Oncology,Autoimmune Diseases Treatment Undisclosed(discovery)
BioGenerationVentures,LifeSciences&HealthFund[Undisclosed/2013]
ACT Biotech Oncology Treatment
Telatinib/BAY57-9352(clinical)ACTB1003(clinical)ACTB1010(IND)ACTB1011(preclinical)
NGNCapital[24 Mn USD/2008]
Actinobac Biomed Oncology,Autoimmune Diseases Treatment Leukothera™
FoundationVenture Capital[0.6 Mn/2012]
Acylin Therapeutics
Oncology,Metabolic,NeurodegeneartionDisorders
Treatment Lysine protein acetyla-tion
ARCHVenturePartners,OVPVenturePartners,WRFCapital[4.4 Mn USD/2011]
Aduro Biotech Cancer,InfectiousDiseases Treatment
CRS-207(clinical)ADU-623(Preclinical)LmProstate(Preclinical)LmMelanoma(Preclinical)STINGVAX(Discovery)
Listeria monocytogenes
Morningside Group[19.2 Mn USD/2011]
Advanced Cell Diagnostics Oncology Diagnostics
RNAscopeHPVHNC(clinical)RNAscopeHPVCC(clinical)RNAscopeMELA(clinical)RNAscopeLCR(discovery)RNAscopeHER2(discovery)CTCscope(discovery)
RNAscope® Morningside Group[5.4 Mn USD/2009]
Morningside Group[12 Mn USD/2012]
Aerpio Therapeutics
Oncology,Retinopathy,InflammatoryDiseases
Treatment AKB-9089(discovery)
AgeChemVentures,AthenianVenturePartners,KearnyVenturePartners,NovartisVentureFunds,TriathlonMedicalVentures,[27 Mn USD/2012]
Affimed Therapeutics
Oncology,InflammatoryDiseases Treatment
AFM-13(clinical)AFM-11(preclinical)AFM-12(preclinical)AFM-20(discovery)
TandAb®
BioMedPartners,LifeSciencesPartners,NovoNordiskBiotech[45 Mn USD/2008]
BioMedPartners,LifeSciencesPartners,NovoNordiskBiotech,OrbiMedAdvisors[26.3 Mn USD/2010]
BioMedPartnersLifeSciencesPartners,NovoNordiskBiotech,OrbiMedAdvisors[20.4 Mn USD/2012]
Agendia BV Oncology Diagnostics
Symphony™BreastCancerSuite(MammaPrint®,BluePrint™,TargetPrint®andTheraPrint®)(approved)ColoPrint®(clinical)
AstraZeneca,AgilentTechnologies,
AXAPrivateEquity,GildeHealthcare,GlobalLifeScience[Undisclosed/2004]
AXAPrivateEquity,GildeHealthcare,GlobalLifeScience[Undisclosed/2005]
AXAPrivateEquity,GildeHealthcarePartners,GlobalLifeScience[Undisclosed/2006]
AXAPrivateEquity,GildeHealthcare,GlobalLifeScience[35 Mn USD/2007]
AXAPrivateEquity,GildeHealthcare,GlobalLifeScience[23 Mn USD/2009]
AXAPrivate,GildeHealthcare,GlobalLifeScience [65 Mn/2012]
Agios Pharmaceuticals
Oncology,GeneticDiseases Treatment Undisclosed(discovery) CelgeneCorporation
ARCHVenturePartners,FlagshipVentures,ThirdRockVentures[33 Mn USD/2008]
ARCHVenturePartners,FlagshipVentures,ThirdRockVentures[8.8 Mn USD/2010]
ARCHVenturePartners,FlagshipVentures,ThirdRockVentures[78 Mn USD/2011]
Table B.1: Funding Series Details and Co-Investors Summary of Active Portfolio Oncology Companies.
O N C O L O G Y D R U G F U N D I N G 2 0 1 3
31OmicsX - Intelligent BioSolutions 49
Company Therapeutic Area Focus Area Exit Year Exit Strategy Value (Mn Usd) Series A Series B Series C Series D Series E Series F NA*
3-Dimensional Pharmaceuticals
Oncology,Inflammation,MetabolicandCardiovascular Diseases
Treatment 2003 AcquiredbyJ&J $88 Rho Ventures
AblynxOncology,Inflammation,Hematology,andPulmonaryDiseases
Treatment 2007 IPO GIMV GIMV GIMV
AcelRx Pain Treatment 2011 IPOPinnacleVentures,SkylineVentures,ThreeArchPartners
PinnacleVentures,SkylineVentures,ThreeArchPartners
Adherex Technologies Oncology Treatment 2007 IPO VIMAC Ventures
Adnexus Therapeutics
Oncology,andImmunology Treatment 2007 AcquiredbyBMS $505
AtlasVenture,FlagshipVentures,HBMHealthcare,PolarisVenture
AtlasVenture,FlagshipVentures,HBMHealthcare,PolarisVenture,Venrock
AtlasVenture,FlagshipVentures,HBMHealthcare,PolarisVenture,Venrock
ADVENTRX Pharmaceuticals
Oncology,andHematology Treatment 2000 IPO Tech Coast Angels
Affitech Oncology,andInflammatoryDiseases Treatment 2010 IPO Teknoinvest
Agennix Oncology,andDiabetescomplications Treatment 2009 IPO Dievini Hopp
Agensys Oncology Treatment 2007 AcquiredbyAstellas $537AltaPartners,HBMHealthcare,NextechInvest
Agenus Oncology,andInfectiousDiseases Treatment 2000 IPO Flagship
Ventures
Alchemia Limited Oncology Treatment 2003 IPO CM Capital Investments
Aldagen Oncology,andCardiovas-cular Disorders Treatment 2012 AcquiredbyCytomedix $40
HarbertVenturePartners,IntersouthPartners,PiedmontAngelNetwork,TallOaksCapitalPartners
AuroraFunds,IntersouthPartners
Alerion Biomedical
Oncology,Cardiovascular,andCNSDisorders Imaging 2006
AcquiredbyARTAdvanced Research Technologies
Undisclosed ResearchCorporationTechnologies
Algeta Oncology Treatment 2007 IPOAdventVenturePartners,BirkVenture,HealthCap
Allos Therapeutics Oncology Treatment 2000 IPO
Abingworth,AislingCapital,NewLeafVenture,SequelVenturePartners,SVLifeSciences
Abingworth,AislingCapital,NewLeafVenture,SequelVenturePartners,SVLifeSciences
Alnylam Pharmaceuticals
Oncology,BleedingDisorders,CardiovascularDisorder,andothers
Treatment 2004 IPO
Abingworth,AtlasVenture,CardinalPartners,PolarisVenture,Roche Venture
Abingworth,ARCHVenturePartners,AtlasVenture,CardinalPartners,PolarisVenture,Roche Venture
Altiris Therapeutics Oncology Treatment 2005 AcquiredbyCelldex
Research Undisclosed BioAdvance
Anesta Corporation CancerPain Treatment 2000 AcquiredbyCephalon $444 Flagship Ventures
AnGes MGOncology,CNS,Cardio-vascularDisorders,andothers
Treatment 2002 IPO MitsubishiUFJCapitalCo
Antisoma Oncology Treatment 2005 IPOCDIBBioScience,HealthCareVentures,Roche Venture
Aposense OncologyMolecular Imaging&Treatment
2010 IPO ClalBiotechnology,MediTechPartners
Table B.2: Funding Series Details and Co-Investors Summary of Exit Portfolio Oncology Companies.
* Key Investors
O N C O L O G Y D R U G F U N D I N G 2 0 1 3
32 OmicsX - Intelligent BioSolutions
ABOUT FUND»»»»» AdamsStreetPartnerisaprivateequityinvestment,em-ployee-ownedprivateequityfirmandisoneofthelargestmanagersofprivateequityforinstitutionalinvestors.
»»»»» AdamsStreetPartners’DirectTeaminvests$5-20millionincompaniesseekingventurecapitalorgrowthequitytoacceleratetheirbusinessesortoprovidepartialliquidityforexistingshareholders.Eachyearroughly10newcom-paniesareprovidedfundsthroughthischannel.
»»»»» Firminvestintofast-growingandlatestagecompaniesintheTechnologyandLifeSciences(Biopharmaceuticals/Medicaldevices)sectors.
»»»»» ThefirmseekstoinvestincompaniespredominantlythatarebasedintheUnitedStates.
»»»»» Itinvestsincompaniesthathavereceivedpriorfinancingfromearly-stageventurefirmsandareseekingadditionalcapitaltofundproductdevelopment&commercialization.
MANAGEMENT PROFILES
Managed By:NAFounded in:1972Focus:DiversifiedFund Type:PrivateEquityTotal Portfolio Companies:157Active Cancer Focused Companies in Portfolio:3Fund under Management:$22,000MnUSDAddress:OneNorthWackerDrive,Suite2200Chicago,Illinois60606-2823U.S.AURL:www.adamsstreetpartners.comEmail:[email protected]:Private
Ticker: NA
GENERAL INFORMATION
Exchange: NA Market Capitalization: NA
Investor Name: AdamsStreetPartners,LLC
Terry GouldHead of Direct [email protected]
Terry Gouldjoinedin1994andistheHeadofDirectInvestmentsformedicaldeviceandbiopharmasectors. HesitsontheBoardsofDirectorsofInclineTherapeutics,Neuraltus,ProteusDigitalandOncoMed.Heisresponsibleforseveralothersuccessfulinvestments: CombiChem,Heartport,INCResearch,JazzPharma,NxStage,Revivant,SpinalDynamicsand Vivant Medical.HedidBAfromDartmouthCollege&MBAfromStanfordUniversity. Assistant: Victoria Long e-mail: [email protected] Linked profile
Michael [email protected]
Michael Lynnjoinedin2007andisresponsibleforsourcingandscreeningprivateequityinvestments in themedicaldeviceandbiopharmaceutical sectors.Mikeserveson theBoardsofDirectorsofLuminousMedical,MyHealthTeams,PivotMedical,PneumRx,Re-vascular,TriRemeandUSGIMedicalandisaBoardObserveratGlobeImmune. He did BA fromCarletonCollegeandMDfromUCLASchoolofMedicine. Assistant: Nancy Thomsen e-mail: [email protected] profile Linked profile
Thomas BremnerPrincipal [email protected]
Thomas Bremner joinedAdamsStreetPartnersin2013andisresponsibleforsourcingandleadinglatestageventureandgrowthequityinvestmentsinthetechnologyandhealthcaresectors.HedidBSfromUniversityofDaytonandMBAfromUniversityofChicagoBoothSchoolofBusiness.Assistant: KirstenCimmarusti e-mail:[email protected]
Linked profileLinked profile
Company Country Key Area Funding (in USD) Year Description Co-Investor
GlobeImmune USA Drug discovery &development
$38.4Mn(SeriesB)$41.2Mn(SeriesC)$10Mn(SeriesD)$17.5Mn(SeriesE)
Jan2006Sep2007May2009Jan2010
Biopharma company develop-ing therapeutic vaccines forthe treatment of cancer andinfectiousdiseases.
HealthCareVentures,BiogenIdec,LillyVentures,Celgene,MorgenthalerVentures,SequelVenture,Genentech,MedicaVenture,PartnersHealthcare,GC&HInvestments,CIDC,PAC-LINKBioVenture,YasudaEnterpriseDevelopment,WexfordCapital,BSISA,MellonFamilyInvestmentCompany,RichardKingMellonFoundation,EminentVentureCapital,BostonLifeScienceVenture,WRFCapital,Generali Financial Holding
CURRENT PORTFOLIO COMPANIES
69
O N C O L O G Y D R U G F U N D I N G 2 0 1 3
33OmicsX - Intelligent BioSolutions
EXIT COMPANIESCompany Country Key Area Funding (in USD) Year Description Co-Investor
Zalicus (formerly CombinatoRx)
USA Drug discovery &development
$40Mn(SeriesB)$30Mn(SeriesC)
2006(IPO)
Abiopharmacompanydevelop-ingtherapiesforthetreatmentofpainandimmuno-inflamma-tory diseases
BostonMillenniaPartners,EastonCapital,YasudaEnterpriseDevelopment,GlobalLifeScienceVentures,CanaanPartners,FlagshipVentures,TLVentures,NovartisBioVentures,GlobalLifeScienceVentures,POSCOBioVentures,CDIBBioScienceVentures,BioVentures Investor
Vivant Medical USA Medical device $19 Mn
(totalfunding)
2005(acquiredbyValley-lab)
Developsmicrowaveablationtechnologyfortheminimallyin-vasivetreatmentofbenignandcanceroussofttissuetumors
CaliforniaTechnologyVentures,Johnson&Johnson,PacificVentureGroup,ThreeArchPartners
Company Country Key Area Funding (in USD) Year Description Co-Investor
Light Sciences Oncology
USA Drug discovery &development
$67Mn(SeriesA)$30Mn(SeriesB)$40.1Mn(SeriesC)
Dec2005Jul2007Jul2008
Engaged in developing light-activateddrugproductsforthetreatmentofcancer.
EssexWoodlandsHealthVentures,JohnsonandJohnson,NovoA/S,ChinaDevelopmentIndustrialBank,LarkspurCapitalCorporation,ScandinavianLifeScienceVenture,NewScienceVentures,LehmanBrothers,Burrill&Co.,DeephavenCapitalManagement,TheMalaysianLifeSciencesCapitalFund
OncoMed Pharmaceuticals USA Drug discovery
&development $169Mn(SeriesB) Dec2008
Clinical stage company devel-oping monoclonal antibodiestargeting cancer stem cells forthetreatmentofcancer.
USVenturePartners,LatterellVenturePartners,VerticalGroup,DelphiVentures,MorgenthalerVentures,DeNovoVentures,BayPartners
70
O N C O L O G Y D R U G F U N D I N G 2 0 1 3
34 OmicsX - Intelligent BioSolutions
ABOUT FUND»»»»» LundbeckfondVentures,whollyownedbytheLundbeckFoundation,isaventurecapitalfirmspecializinginearlystageinvestmentsinlifesciencecompanies.
»»»»» Itmakeinvestmentswithinlifesciencesector,focusingonpharmaceuticals,biopharmaceuticals,medtechanddiagnosticscompanies.
»»»»» LundbeckfondVenturesinvestsupto€50Mnincompa-niesprimarilylocatedintheNorthernEurope.
»»»»» Itspresentportfolioconsistsof12companiesintheac-tivemodeofinvestmentfromvarioustherapeuticareas.
MANAGEMENT PROFILES
Mette Kirstine Agger Managing [email protected]
Mette Kirstine Agger isManagingPartnerofLundbeckfondVentures.ShewaspreviouslyCo-FounderandCEOof7TMPharmaandhasabroadinternationalexperiencewithinbiotech/lifesciencecoveringbusinessdevelopmentandlicensing,managementandfinancing.Prior,MettewaspartofthemanagementteamofNeuroSearchresponsibleforbusinessdevelopmentandlicensing.ShestartedhercarrierasPatentAgent.MettehasbeenappointedtonumerousboardpositionsbothinprivateandpubliccompaniesincludingAllocure,PsioxusandVeloxis.SheisanM.B.AandisgraduatedasBiologistfromtheUniversityofCopenhagen.
Linked profile
Managed By:LundbeckfondVenturesFounded in:2009Focus:LifeSciencesFund Type: Venture CapitalCurrent Total Portfolio Companies:12Active Cancer Focused Companies in Portfolio:4Fund under Management:$1-$100MnUSDAddress:Vestagervej17DK-2900Hellerup,DenmarkURL:www.lundbeckfondventures.comEmail: [email protected]:Private
Ticker: NA
GENERAL INFORMATION
Exchange:NA Market Capitalization: NA
Investor Name: LundbeckfondVentures
Johan Kördel Senior [email protected]
Johan Kördel isSeniorPartnerofLundbeckfondVentures.HewaspreviouslyCo-FounderandCEOofSoundBiotechandCo-FounderandSeniorVPofResearchandBusinessDevelopmentofBiovitrum.PriortothesepositionsheworkedalmostadecadeinPharmacia.Johanhasco-foundedotherbiotechcompaniesandbeenappointedtonumerousboardpositionsboth inprivateandpublic companies.Presently,he is aboardmemberofAcaciaPharma,Celladon,Enterome,RiverVisionandSyntaxin.HeisanassociateprofessorinPhysicalChemistryattheUniversityofLund,Sweden.
Linked profile
Company Country Key Area Funding (in USD) Year Description Co-Investor
Acacia Pharma U.K Cancer
management $10Mn(SeriesA) Mar2011Pharmaceutical company specialisinginthedevelopmentofdrugsforcancersupportivecare.
Glide Healthcare
PsiOxus Therapeutics U.K Drug discovery
&development $34Mn(SeriesB) Jul2012
Development-stage biotech company,developingtherapeuticvaccinesforthetreatmentofcanceranditsrelatedcon-ditions.
ImperialInnovationsGroup,InvescoPerpetual,SROne
DySIS Medical UK Diagnostics $11.6Mn
(Undisclosed) Apr2013
Medical device company that develops andmanufactures imaging systems fo-cusing on the detection of cancerousandpre-cancerouslesions.
AlbionVentures,NBGI,theScottishInvestmentBank
Syntaxin UK Drug discovery &development $27Mn(SeriesC) Nov2010
Biopharma company developing bio-logic drugs (Targeted Secretion Inhibi-tors)forthetreatmentofvariousdisor-ders,includingcancer.
SeventurePartners,Ipsen,Abingworth,SROne,LifeSciencePartners,Johnson&JohnsonDevelopmentCorporation,QuestforGrowth,
CURRENT PORTFOLIO COMPANIES
323